DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Nipent (Pentostatin) - Disability - Suspected Cause - Side Effect Reports

 
 



Index of reports > Disability (1)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Nipent (Pentostatin) disability. The selected reports were submitted to the FDA during the sample period of about a year.

Possible Nipent side effects in male

Reported by a health professional (non-physician/pharmacist) from United States on 2011-12-01

Patient: male, weighing 127.4 kg (280.3 pounds)

Reactions: Dysphagia, Blood Lactate Dehydrogenase Increased, Alanine Aminotransferase Increased, Muscular Weakness, Polymyositis, Connective Tissue Disorder, Musculoskeletal Disorder, Aspartate Aminotransferase Increased, Blood Uric Acid Increased, Mastication Disorder

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Nipent
    Dosage: 10 mg, not reported
    Indication: Chronic Lymphocytic Leukaemia
    Start date: 2011-09-01
    End date: 2011-09-01

(Rituximab)
    Dosage: 945 mg, not reported
    Indication: Chronic Lymphocytic Leukaemia
    Start date: 2011-09-01
    End date: 2011-09-01

Cyclophosphamide
    Dosage: 1512 mg, not reported
    Indication: Chronic Lymphocytic Leukaemia
    Start date: 2011-09-01
    End date: 2011-09-01

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017